Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease
Description
The presentation discusses the cutaneous manifestations of systemic disease, focusing on a case involving a 46-year-old man with newly diagnosed follicular lymphoma and painful oral lesions. Medications were ineffective, and various diagnostic tests were performed, including biopsies, immunofluorescent studies, and serological testing. The potential diagnosis considered was perineoplastic pemphigus, an autoimmune blistering disease associated with underlying malignancies, particularly lymphoproliferative disorders. This condition can lead to severe complications like bronchiolitis obliterans, characterized by respiratory failure due to airway obstruction and inflammation. The discussant emphasized the importance of recognizing perineoplastic pemphigus in patients with oral erosions linked to malignancies, even when serological tests are negative. The presentation highlighted the need for a combined therapeutic approach involving high-dose steroids, rituximab, and possibly other immunosuppressants, as outcomes remain poor and can lead to high mortality rates from infections or respiratory failure. Successful management requires close monitoring and collaboration with oncologists.
View moreConclusions
- Paraneoplastic pemphigus is a serious autoimmune blistering disease associated with underlying malignancies, especially lymphoproliferative disorders.
- Initial negative antibody testing should not rule out paraneoplastic pemphigus; clinical suspicion remains critical.
- Management of patients requires a multidisciplinary approach, balancing cancer treatment with autoimmune disease management.
- Both T-cell and B-cell mediated mechanisms contribute to the disease pathogenesis of paraneoplastic pemphigus.
- Common extracutaneous complications include bronchiolitis obliterans, leading to poor prognosis in affected patients.
- Patients with paraneoplastic pemphigus often require high doses of corticosteroids and may benefit from therapies targeting both humoral and cell-mediated responses.
- Ongoing monitoring for organ involvement is essential in managing patients with paraneoplastic pemphigus.
- Huang S, et al. J Am Acad Dermatol. 2023;S0190-9622(23)02685-3.
- Poot AM, et al. Br J Dermatol. 2013;169(5):1016-24.
- Anderson HJ, et al. J Am Acad Dermatol. 2023;S0190-9622(23)02512-4.
- Kaplan I, et al. Oral Oncol. 2004;40(6):553-62.
- Anhalt GJ, et al. N Engl J Med. 1990;323(25):1729-35.
- Nguyen VT, et al. Arch Dermatol. 2001;137(2):193-206.
- Chan LS. Arch Dermatol. 2000;136(5):663-4.
- Okahashi K, et al. Br J Dermatol. 2022; 176(5):1406-1409.
- Cummins DL, et al. J Am Acad Dermatol. 2007;56(1):153-9.
- Gambichler T, et al. Curr Oncol. 2022;29(4):2395-405.
- Svoboda SA, et al. J Cutan Pathol. 2021;48(9):1133-8.
- Antiga E, et al. J Eur Acad Dermatol Venereol. 2023;37(6):1118-34.
- Ouedraogo E, et al. J Am Acad Dermatol. 2019;80(6):1544-9.
- Leger S, et al. Arch Dermatol. 2012;148(10):1165-72.
- Wang M, et al. Acta Derm Venereol. 2020;100(18):adv00312.